FDA turns down Hetlioz for jet lag once again Vanda will continue to push for approval of Hetlioz for jet lag, despite the FDA saying its trial designs were not satisfactory.

#VandaPharma may have forced the #FDA to revisit its marketing application for #Hetlioz as a therapy for #jetlag, but the outcome has remained the same.

pharmaphorum.com/news/fda-tur...

Vanda ends 40-year hiatus for new motion sickness drugs The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.

The FDA's usual end-of-year flurry of #regulatoryapprovals is a little lighter than usual, but the agency has delivered some end-of-year cheer to #VandaPharma after giving the go-ahead to its drug for #motionsickness.

pharmaphorum.com/news/vanda-e...

Vanda Scores Major Court Victory Against FDA, Paving Path for Jet Lag Treatment Vanda Pharmaceuticals (NASDAQ: VNDA), announced a landmark win as the U.S. Court of Appeals overturned the FDA’s refusal to approve HETLIOZ® (tasimelteon) fo

(NASDAQ: #VNDA)
#VandaPharma wins big as the U.S. Court of Appeals overturns the FDA’s jet lag drug rejection. HETLIOZ® could become the first approved jet lag treatment, unlocking a major new market.
prismmarketview.com/vanda-scores...